Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure.
The B-type natriuretic peptide (BNP) and the amino-terminal fragment of proBNP (NT-proBNP) are increased in heart failure in proportion to severity of symptoms, degree of left ventricular dysfunction, and elevation of cardiac filling pressures. These natriuretic peptides (NPs) are increasingly used for diagnostic and prognostic purposes in acute heart failure. While NP levels on admission provide independent prognostic information, serial determinations during hospitalization and at discharge better reflect adequacy of treatment and prognosis. The addition of BNP and NT-proBNP to usual clinical decision making enhances detection of high-risk patients who need aggressive follow-up and adjustment of treatment.
Cardiomyopathy Program, Loma Linda University Medical Center, Loma Linda, CA 92354, USA. jchiong@llu.edu
Jun R
JR
Chiong
Geoffrey T
GT
Jao
Kirkwood F
KF
Adams
D000208:Acute Disease; D003920:Diabetes Mellitus; D004417:Dyspnea; D004636:Emergency Service, Hospital; D006333:Heart Failure / Q000175:diagnosis* / Q000191:economics / Q000473:pathology; D006801:Humans; D007676:Kidney Failure, Chronic; D020097:Natriuretic Peptide, Brain; D010446:Peptide Fragments; D011379:Prognosis; D018570:Risk Assessment; D014481:United States; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis / Q000473:pathology
D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain